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Zaire ebolavirus causes large outbreaks of severe and usually fatal hemorrhagic disease in humans for which there is no effective
treatment or cure. To facilitate examination of early critical events in viral pathogenesis and to identify antiviral compounds, a recombinant
Zaire ebolavirus was engineered to express a foreign protein, eGFP, to provide a rapid and sensitive means to monitor virus replication in
infected cells. This genetically engineered virus represents the first insertion of a foreign gene into ebolavirus. We show that Ebola-eGFP
virus (EboZ-eGFP) infects known early targets of human infections and serves as an ideal model to screen antiviral compounds in less time
than any previously published assay.
Published by Elsevier Inc.
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The emerging viral pathogens Ebola virus (EboV) and
Marburg virus (MbgV) (family Filoviridae) are known to
cause devastating disease in human and non-human
primates. In humans, signs and symptoms of Ebola
hemorrhagic fever (EHF) can include gastrointestinal
(nausea, abdominal pain), respiratory (shortness of breath,
cough) vascular (mucosal hemorrhages, visceral hemorrha-
gic effusions, coagulopathy), and central nervous system
(headache, dementia, coma) manifestations (Sanchez et al.,
2001). The case fatality ranges between 50% and 90% for
some species of EboV with death typically occurring
quickly, within 7 to 10 days after onset of symptoms. Due0042-6822/$ - see front matter. Published by Elsevier Inc.
doi:10.1016/j.virol.2004.10.048
* Corresponding author. Mailstop G14, Division of Viral and
Rickettsial Diseases, Centers for Disease Control and Prevention, 1600
Clifton Road, Atlanta, GA 30333, USA. Fax: +1 404 639 118.
E-mail addresses: stn1@cdc.gov, jit8@cdc.gov (S.T. Nichol).to the severity of the disease, the rapid onset of symptoms,
and the ease of human to human transmission, these viruses
are studied exclusively under biosafety level 4 (BSL-4)
containment and are listed on the Centers for Disease
Control and Prevention (CDC) Category A list of potential
bioterrorist agents. Early viral amplification is thought to
occur in mononuclear phagocytes and dendritic cells,
followed by massive liver and spleen infection. In some
cases there is significant endothelial cell infection and
leakage (hemorrhage) in addition to blood coagulation
abnormalities such as disseminated intravascular coagula-
tion (Geisbert et al., 2003; Sanchez et al., 2001; Zaki and
Goldsmith, 1999). Unfortunately, the mechanisms under-
lying the severe pathogenesis are only partially understood,
highlighting the need to further understand viral replication,
especially the early critical events in an infection, as well as
develop effective antiviral therapies. Currently, there is no
effective antiviral therapy for humans infected with either
EboV or MbgV, although there have been a number of005) 20–27
Rapid Communication 21compounds shown to exhibit specific antiviral properties in
tissue culture infections and animal models. One class of
inhibitors specifically targets virus entry by interfering with
proposed interactions between the highly glycosylated viral
glycoprotein (Barrientos et al., 2003) and the cellular C-type
lectin adhesion molecules DC-SIGN and L-SIGN. Treat-
ment of cultured cells with either of two compounds in this
class, cyanovirin-N (CV-N) or BH30sucMan, result in a
dramatic inhibition of virus entry (Barrientos et al., 2003;
Lasala et al., 2003). Overall, however, the success of these
two drugs is limited. When CV-N is used to treat EboV-
infected mice, death is delayed but not prevented (Barrien-
tos et al., 2003). Complete protection of mice is achieved
using a different type of inhibitor, S-adenosylhomocysteine
hydrolase (SAH) (Bray et al., 1999; Huggins et al., 1999)
although it is effective only when mice are treated the day
before or the day of virus challenge. The antiviral effect of
SAH inhibitors was first thought to be due to reduced
methylation of the 5V cap of viral messages, but Bray et al.
(2002) now believe the antiviral properties may be attributed
to an increase in IFN-a production, consistent with the
protective role of the innate immune response in the mouse
model of EboV infection (Mahanty et al., 2003). To date,
these compounds have not shown efficacy in non-human
primate models. More recently, using a non-human primate
model, Geisbert et al. (2003) have demonstrated a partial
amelioration of EHF in rhesus monkeys using recombinant
nematode anticoagulant protein C2 (rNAPc2), a potent
inhibitor of tissue factor-initiated blood coagulation. This
treatment regime increased survival from 6% to 33% of
treated animals. One of the major stumbling blocks towards
the goal of developing more effective therapies has been the
lack of a sensitive high-throughput assay to measure the
effects of potential antiviral compounds. The assays
currently in use for such purposes take a week (Barrientos
et al., 2003; Huggins et al., 1999) and only measure virus
replication indirectly by monitoring cytopathic effect (CPE)
or cellular neutral red uptake. In this study, we have usedFig. 1. The schematic diagram depicts eGFP insertion into the full-length Zaire ebo
3V UTR. Diagram also shows the approximate location of the inserted transcriptioreverse genetics to generate a full-length cDNA clone of
Zaire ebolavirus into which we inserted a foreign reporter
gene, eGFP. Although eGFP has been successfully inserted
into genomes of other (smaller) single-strand negative sense
RNA viruses, EboV is almost 19 kb in length and we were
uncertain if the genome size would create constraints for
insertion of foreign genes. However, virus rescue from this
clone (EboZ-eGFP virus) was successful, and we found that
it grows similarly to that of wild-type EboV yet causes
infected cells to fluoresce brightly. EboZ-eGFP virus thus
provides a rapid, sensitive, and quantitative readout of virus
replication and dissemination in infected cells that will
allow examination of early pathogenic events and high-
throughput drug screening in less time than any previously
described assay. In addition, this is the first description of an
insertion of a foreign gene of any kind into a member of the
family Filoviridae.Results
Generation of infectious clone and virus rescue
We successfully generated and rescued virus from a full-
length clone of Zaire ebolavirus (Mayinga strain) into which
we cloned a BsiW1 restriction site present in the NP 3V UTR
(Fig. 1). This bwild-type likeQ virus was termed EboZ-
BsiW1. The BsiW1 restriction site was then used to insert
the eGFP open reading frame preceded by a 90-nucleotide
fragment containing an authentic transcription stop
sequence, to direct the termination of the NP mRNA, and
a transcription start sequence to direct the initiation of the
eGFP message. Compared to rescue of non-eGFP express-
ing EboZ-BsiW1 virus, monitoring virus rescue from the
pEbola-eGFP clone was simple and rapid. Within 48–72 h
after transfection, usually 5–15 cells per well of a 6-well
dish would fluoresce brightly. If we used CPE to monitor
virus rescue, for either EboZ-eGFP or EboZ-BsiW1, welavirus ’76 Mayinga clone at the introduced BsiW1 restriction site in the NP
nal stop and start signals to facilitate NP and eGFP expression.
Rapid Communication22typically had to wait 5–10 days after passage of the
transfected cell supernatant onto uninfected Vero E6
monolayers, consistent with the results of others (Neumann
et al., 2002).
Characterization of EboZ-eGFP growth properties in Vero
E6 cells
In order to determine the utility of eGFP expression as an
effective reporter for virus infection, Vero E6 cells were
infected at a multiplicity of infection (MOI) of two and
monitored at various times post-infection for eGFP fluo-
rescence. As shown in Fig. 2A, the expression of eGFP in
infected cells is both rapid and robust, thus allowing simpleFig. 2. Demonstration of eGFP fluorescence in infected Vero E6 cells. (A) EboZ-eG
using either fluorescent or brightfield microscopy. (B) Brightfield and fluorescentdiscrimination of infected cells within 24 h. Similarly, virus
plaques are also easy to identify and quantitate in the
absence of any immuno- or neutral red staining (Fig. 2B).
Because the eGFP ORF was inserted immediately after
the NP gene all downstream viral genes might be
expected to be downregulated due to the sequential and
polarized gene expression characteristic of single-strand
negative sense RNA viruses. For this reason, the growth
properties of EboZ-eGFP could be attenuated. In order to
examine this possibility, a single cycle growth analysis of
EboZ-eGFP was performed side-by-side with EboZ-
BsiW1 virus as well as wild-type Mayinga ’76 Zaire
ebolavirus (EboZ-wt). As shown in Fig. 3A, growth
analysis reveals that EboZ-eGFP growth kinetics areFP and EboZ-BsiW1 infections at 18, 32, and 48 h post-infection monitored
microscopy of a day 7 plaque of EboZ-eGFP immobilized under 1% agar.
Fig. 3. (A) Time course of Vero E6 cells infected with EboZ-eGFP, EboZ-BsiW1, or EboZ-wt. Vero E6 cells were infected at a MOI of two and virus titers in
the supernatants were determined at the indicated times post-infection. (B) Fluorescent microscopy of human PBMCs either mock-infected or infected with
EboZ-eGFP and analyzed at the indicated times post-infection. (C) Electron micrograph of a human macrophage infected with EboZ-eGFP virus.
(*, nucleocapsid inclusion. Scale bar, 1 Am). (D) At a higher magnification of area pointed to (boxed) in (C), ebolavirus particles are clearly visible (arrow)
(Scale bar, 100 nm).
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EboZ-BsiW1. Consistent with the single cycle growth
analysis, the plaque morphology of EboZ-eGFP was
indistinguishable from that of either of the other two
viruses tested (data not shown). In addition, we studied
the genetic stability of eGFP expression by undiluted
passaging of the virus multiple times in Vero E6 cells.
After 25 passages with no major diminuation of eGFP
signal in infected cells (data not shown), it was concluded
that the eGFP insertion was stable. Some slight variations
in eGFP intensity were observed from one passage to the
next. However, these variations were not consistent and
were likely the result of replication interference by
defective interfering particles accumulated during undi-
luted virus passage as has been previously demonstrated
for EboV (Calain et al., 1999).EboZ-eGFP infection of human PBMCs
One of the primary goals for inserting eGFP into EboV
was to generate a virus with growth and tropism properties
similar to that of wild-type virus, but whose replication
would be more easily and rapidly visualized. Early critical
events in human and animal infections are largely unknown
due to the difficulty in detection of cells infected soon after
exposure. A virus such as EboZ-eGFP could be useful for
demonstrating primary sites of replication in animal model
infections. Previous studies have identified monocytes and
macrophages as primary targets for filovirus infection in
human and animal models (Connally et al., 1999; Feldmann
et al., 1996; Geisbert et al., 2003; Gupta et al., 2001; Jaax et
al., 1996; Stroher et al., 2001; Zaki and Goldsmith, 1999).
Therefore, to further investigate if EboZ-eGFP virus infects
Rapid Communication24the same known early targets of wild-type Zaire ebolavirus,
human PBMCs isolated from healthy volunteers were
infected in vitro with 1 MOI of EboZ-eGFP. The results
of this analysis are shown in Fig. 3B in which rapid green
fluorescence of adherent PBMCs is detected within 24 h
post-infection. Subsequent FACS analysis revealed that
within 24–48 h, approximately 30% of class II+ cells were
GFP+, and of these class II+ GFP+ cells, none were B cells
by CD19 co-staining (data not shown). As it is well
established that HLA class II+ cells consist primarily of B
cells, dendritic cells, and macrophages, these data indicate
that macrophage and dentritic cells are the likely viral
targets within the PBMC population. To re-confirm the size
of the macrophage population within class II+ cells, we
stained class II+ cells for the macrophage marker CD14 and
found that approximately 30% cells were CD14+. Further
electron microscopy analysis of PBMCs infected with
EboZ-eGFP confirm that macrophages are infected. As
shown in Fig. 3C and D, EboZ-eGFP virus production in
human macrophages is evidenced by the presence of viral
nucleocapsid inclusions and the generation of mature viral
particles.
A rapid assay for screening antiviral compounds
As a proof of principle for using the EboZ-eGFP virus to
rapidly screen antiviral compounds, consensus interferon
alpha (conIFN-a), a compound with known EboV antiviral
properties, was used at multiple concentrations to treat Vero
E6 cells infected with either EboZ-eGFP virus or a control
Zaire ebolavirus. The infected cells were monitored for
evidence of virus replication by either fluorescence micro-
scopy (for EboZ-eGFP virus) or a previously published CPE-
based assay (Huggins et al., 1999). Using a logit4 computer
algorithm as previously described (Huggins et al., 1999;
Paragas et al., 2004), the IC50 values were determined on
days 1 and 2 using the EboZ-eGFP assay and on day 7 using
the CPE-based assay. The signals to background level for
each assay are presented in a graph shown (Fig. 4A) along
with the calculated IC50 values determined by each method
(Fig. 4B). For the EboZ-eGFP assay, the data show anFig. 4. (A) A time-dependent line graph of the signal to background ratio of the CP
signal to background versus time.overall signal to background ratio of approximately 12:1
within the first 48 h, ultimately reaching a level of 16:1. By
contrast, the CPE-based assay requires 7 days to reach a
stage where the effect of virus replication can be measured, a
point at which the signal to background ratio is approx-
imately half of that obtained using the EboZ-eGFP assay.Discussion
In this study, we report the first insertion of a foreign
gene, eGFP, into Zaire ebolavirus. This was achieved by
first generating a full-length clone of Zaire ebolavirus, strain
Mayinga, and inserting eGFP as an extra transcription unit
in between the NP and VP35 genes. These results show that
the initial concern about size limitations for insertion of a
foreign gene into an already large (approximately 19 kb)
genome were unfounded. Insertion of eGFP into EboV
extended the upper size limit of filovirus genomes to 19,773
nucleotides. Surprisingly, single-step growth analysis in cell
culture revealed that the recombinant virus showed no
detectable attenuation in either the rate of growth or the
ultimate titers reached. The reporter gene expression is
stable over many passages, consistent with previous reports
of foreign gene insertions in other single-strand negative
sense viruses (Duprex et al., 1999). Infection of human
PBMCs demonstrated that EboZ-eGFP virus infects macro-
phages, an early target in human infections. Furthermore,
we showed that infection of human macrophages is easily
detectable within 24 h due to the robust eGFP fluorescence
present in infected cells.
After establishing that EboZ-eGFP virus behaves in a
manner similar to that of wild-type Zaire ebolavirus in tissue
culture and in vitro human PBMC infections, we demon-
strated in proof of principle that this recombinant virus
serves as an effective tool to screen compounds for antiviral
properties. The data presented clearly demonstrate that the
ability to monitor the progression of an ebolavirus infection
is greatly enhanced by the generation of eGFP as a reporter
of virus replication. This robust signal allowed the
calculation of consistent IC50 values in less than a quarterE-based and the eGFP fluorescent-based drug discovery assays. The axes are
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readout afforded by the EboZ-eGFP virus is an important
feature, not only to reduce the overall time needed for
screening compounds on a high throughput basis, but also to
measure viral inhibition of compounds with short half-lives.
Many potential drugs will degrade and/or become inactive
well before the 7 days required for completion of the CPE-
based assay, thus allowing for variable levels of virus
recovery during the period between drug inactivation and
the time of neutral red uptake. This in turn could lead to a
less accurate calculation of the IC50 values. An additional
attribute of the EboZ-eGFP virus is that, compared to the
CPE-based assay, eGFP fluorescence is directly indicative
of virus replication because it is a gene product wholly
dependent, and thus proportional to, viral RNA replication
and transcription. CPE on the other hand is a product of
multiple downstream cellular events brought about by the
action and accumulation of viral gene products, such as the
glycoprotein, and is therefore much delayed in appearance
compared to virus replication itself.
We anticipate EboZ-eGFP virus will also be of great
value with pathogenesis studies, particularly those focused
on critical early events in animal-model infections including
non-human primates. The natural reservoir for Zaire
ebolavirus, or any filovirus for that matter, remains to be
elucidated. EboZ-eGFP virus could be very useful for
detecting horizontal and/or vertical transmission following
experimental infections of candidate reservoir species. The
fluorescence of the eGFP signal should be more robust to
that observed by standard immunohistochemistry (IHC), as
has been shown for eGFP-expressing measles virus in
infected astrocytoma cells (Duprex et al., 1999), and should
therefore complement standard IHC methods. Secondly,
sample preparation and analysis should be considerably
faster and easier because tissue fixation and antibody
incubations will not necessarily be required.Material and methods
Generation of the full length clone, insertion of eGFP and
virus rescue
The full-length clone was generated from multiple
cDNA fragments derived from total RNA isolated from
cells infected with the 1976 Mayinga strain of Zaire
ebolavirus. The cDNA fragments were ligated together
using conventional cloning techniques to form three
subgenomic clones roughly corresponding to NP-GP, GP-
L, and L. The three subgenomic clones were then
sequentially ligated together to form a full-length positive
sense clone under the control of a phage T7 promoter
followed by a single non-viral G residue. The L sequence
was followed by a hepatitis delta ribozyme and T7
transcription terminator. The sequence of the full-length
clone was compared to a previously determined sequencefor the ’76 Mayinga strain of Zaire ebolavirus which is
identical to that listed by Volchkov et al. (GenBank
accession numberNC002549). In total, there were seven
nucleotide changes in addition to the three nucleotide
insertions used to generate the BsiW1 restriction site. All
but one of the seven changes were in non-coding sequences
and were left in the full length clone to serve as genetic
markers. The changes were G to C at nt 2833, A to G at nt
3803, A to G at nt 4187, T to C at nt 11193, G to A at nt
14187, and a T deletion at nt 18614. The single G to A
mutation at position 18138 conferred an M to I amino acid
change near the C-terminus of L. This mutation was first
noted in a working (plaque purified) laboratory virus stock
derived from the original ’76 Mayinga strain and does not
affect virus growth in infected tissue culture cells.
To insert the eGFP open reading frame (ORF), a BsiW1
restriction site was introduced into the NP 3V UTR by
inserting the nucleotides 5V-AGC-3V between nucleotides
2851 and 2852. This insertion was performed using PCR
to generate two overlapping fragments of ebolavirus
sequence with a common BsiW1 site which were sub-
sequently ligated into the NP-GP subclone using the Nde1
and Xho1 sites in NP and VP35, respectively. The primers
Ebo2407(+) 5-CTCTTTTGAGGAGATGTATCG-3V and
NP3VNCRBsiW1(-) 5V-GTATGACGTACGGCTAGTA-
ATAATAAGG-3V were used for the first fragment, while
the second fragment was amplified by using the primers
NP3 VNCRBsiW1(+) 5 V-GACTCTCGTACGTTTT-
CAAAGTTCAATTTGAG-3V and Ebo4105(-) 5V-ATACC-
CAACCTCGATCAATC-3V. The eGFP ORF was then
inserted into the newly introduced BsiW1 restriction site
present in the NP 3V UTR along with an approximately 90
nucleotide duplicate set of mRNA transcription start (3V-
CGCUACUUCUAAUU-5V) and poly A (3V-UAAUU-
CUUUUUU-5V) signals normally located between the
VP40 and GP ORFs. The 90-nucleotide fragment was
generated by annealing the oligo 5VGTACGTGCCCTTCQ
TAATTAAGAAAAAATCGGCGATGAAGATTAAGCCG-
ACAGTGAGCGTAATCTTCATCTCTCTTAGATTA-
TTTGTTTTC 3V and the oligo 5VCATGGAAAACAAAT
AATCTAAGAGAGATGAAGATTACGCTCACT-
GTCGGCTTAATCTTCATCGCCGATTTTTTCTTAATTA-
GAAGGGCAC 3V. When annealed, the oligos had
overhangs compatible with BsiW1 and Nco1. The eGFP
DNA fragment was amplified by PCR using the oligos
Nco1eGFP(+) 5V TACCGGTCGCCACCATGGTGAG-
CAAGG 3Vand BsiW1eGFP(-) 5V TAATACCGTACGTT-
ACTTGTACAGCTCGTC 3V to place a Nco1 and BsiW1
site at the N and C-terminus of eGFP, respectively. The
eGFP fragment along with the 90-nucleotide cassette was
ligated into the BsiW1 site present in the NP-GP subclone.
Virus was rescued by transfecting a 50/50 mixture of
293T and Vero E6 cells as previously described (Neumann
et al., 2002). CPE generally appeared within 5–9 days after
the passage of the transfected cell supernatants. Expression
of eGFP was monitored by fluorescence microscopy.
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The wild type T76 Mayinga strain of Zaire ebolavirus
used in the single-cycle growth analysis was passaged three
times in Vero E6 cells. The mouse adapted Zaire ebolavirus
has been described elsewhere (Bray et al., 1999). EboV
rescued from full-length clones were passaged 1–2 times in
Vero E6 cells.
Single step growth analysis
Vero E6 cells were seeded in 24-well dishes using one
24-well dish for each virus tested. Cells were infected at a
MOI of 2. After an initial 2 h adsorption at 37 8C in 1 ml of
media (DMEM/2% FCS), each well was washed two times
with PBS followed by the addition of 1 ml of media. The
plates were then incubated at 37 8C. For each of the
indicated time points, duplicate wells were harvested by
adding 10 Al of 1 M Tris pH 8 and removing approximately
500 Al (in duplicate 250 Al aliquots) of supernatant and
freezing at 80 8C. After all the time points were collected,
the virus titers were determined by immunoplaque assay as
previously described (Towner et al., 2004).
Infection of human PBMCs
Apharesis from healthy donors was layered on Ficoll
gradient medium (ICN-biomedical Inc., Aurora, OH) in 1:1
ratio to isolate peripheral blood mononuclear cells
(PBMCs). Purified PBMCs were plated in a 24-well plate
(3  106 cells/well) and left for plate adherence at 37 8C for
1 h in a CO2 incubator. Adherent cells were infected with 1
MOI of EboZ-eGFP virus (or medium for control wells) for
45 min at 37 8C with rocking followed by removal of non-
adsorbed virus and subsequent add-back of non-adherent
cells. Cells were examined for eGFP expression at 24, 48,
72, and 96 h post-infection. EGFP-expressing cells were
analyzed for cell surface markers by labeling with either
phycoerythrin (PE) or allophycocyanin (APC) conjugated
antibodies specific for CD14, HLA-DR, CD19, and CD3.
Cells were acquired on FACS Caliber and analyzed on Cell
Quest software.
For electron microscopy, infected and uninfected PBMCs
were pelleted, fixed, and embedded by standard methods
and analyzed (Goldsmith et al., 2003).
Drug screening assay
The GFP-based virus drug discovery assay is a mod-
ification of previously described 96-well plate assays. In
vitro cell cultures of Vero E6 cells in 96-well plates were
infected with EboZ-GFP or control virus (Zaire ebolavirus-
mouse adapted) at an MOI of 0.1. The test antiviral
compound was then added to infected cultures in a range
of dilutions designed to flank the predicted IC50. The IC50
was determined using a 4 parameter logit algorithm. Every24 h for 7 days post-infection, plates were stained with
neutral red or read in the fluorescent plate reader set at 450
nm (emission) and 515 nm (excitation). The neutral red was
added to cells at a concentration of 1.11 mg/ml dissolved in
PBS. After a 2-h incubation, cells were washed two times
with ice-cold PBS. The retained stain was solubilized by
adding 100 Al of a 1:1 mixture of 0.001 M ammonium
phosphate and ethanol. An optical density was obtained at a
wavelength 450 nm using a plate reader.Acknowledgments
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